Andra AP fonden increased its stake in Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) by 78.6% in the

Fifth Third Bancorp grew its position in Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) by 7,433.9% in

Allspring Global Investments Holdings LLC grew its stake in Alnylam Pharmaceuticals, Inc. (NASDAQ: A

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi th

I initiate coverage of Alnylam Pharmaceuticals with a non-consensus BUY rating, citing the recent pu

− Initiates Global Phase 2 APPlauDS Study of Mivelsiran in Down Syndrome–Associated Alzheimer’s Dise

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi th

B of A Securities analyst Tazeen Ahmad maintains Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Buy

When a late-stage clinical trial misses a primary endpoint, the market reaction rarely distributes e

Truist Securities analyst Danielle Brill maintains Alnylam Pharmaceuticals (NASDAQ:ALNY) with a B

HC Wainwright & Co. analyst Patrick R. Trucchio maintains Alnylam Pharmaceuticals (NASDAQ:ALN

Ionis and AstraZeneca's Phase 3 ATTR-CM trial misses its primary goal, analyst says the outcome

Morgan Stanley analyst Michael Ulz maintains Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Equal-W

CNBC's Jim Cramer pushed viewers away from the usual semiconductor and hyperscaler chatter.

U.S. stocks higher, Nasdaq up 150+ points. Aehr Test Systems shares rose 13.6%. Other big gainers in

Gainers Virax Biolabs Group (NASDAQ:VRAX) stock increased by 134.0% to $7.44 during Thursday's

AstraZeneca and California-based biotech Ionis Pharmaceuticals announce a late-stage trial failure f

Stocks moving: RPGL +54.5%, EDBL +42.5%, SDOT +27.4%, BJDX +24.6%, AP +19.9%, SUNE +18%, ALNY +15.3%

ALNY's advancing pipeline and partnered programs can expand future revenue sources alongside its gro

The company has six marketed therapies and several others in late-stage clinical trials. Alnylam has

Top Wall Street analysts upgraded and downgraded several top companies, including Applied Materials,

HC Wainwright & Co. analyst Patrick R. Trucchio maintains Alnylam Pharmaceuticals (NASDAQ:ALN

Alnylam Pharmaceuticals, Inc. (ALNY) Discusses ALN-6400 RNAi Therapy Targeting Plasminogen for Rare

Expanded agreement extends Marmot across key enterprise functions, advancing a new operating model f

NEW YORK & SAN FRANCISCO--(BUSINESS WIRE)-- #AI--Komodo Health®, the leader in AI-powered healthcare

Alnylam Pharmaceuticals (NASDAQ:ALNY) has outperformed the market over the past 10 years by 3.79% on

Amvuttra is the primary driver of ALNY's revenues, but growth from Givlaari, Oxlumo and Leqvio may h

In this week's edition of InnovationRx, we look at biotech M&A, the rise of India's Anthem Bioscienc

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investi

Amvuttra's blockbuster growth is reshaping ALNY's revenue mix, and fresh ATTR-CM approvals can unloc

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi th

ATHENS, Greece--(BUSINESS WIRE)--GENESIS Pharma Expands Strategic Commercial Partnership with Alnyla

Alnylam Pharmaceuticals, Inc. (ALNY) Presents at Goldman Sachs 47th Annual Global Healthcare Confere

U.S. stock futures down, Nasdaq 100 falls over 100 points. Mach Natural Resources LP (MNR) shares di

The Nasdaq-100 Index has announced its annual reconstitution, with six new companies being added and

As a result of the reconstitution, the following six companies will be removed from the Index: Bioge

Novo Nordisk's Coramitug cut NT-proBNP levels and was well tolerated in a Phase 2 ATTR-CM trial,

Intellia Therapeutics (NASDAQ: NTLA) paused their Phase 3 MAGNITUDE and MAGNITUDE-2 trials after a s

  During the session on Thursday, 461 stocks hit new 52-week lows.

Stocks Which Set New 52-Week Low Yesterday, October 9th